CNS metastases in breast cancer

Journal of Clinical Oncology

Volumn 22, Issue 17, 2004, Pages 3608-3617

  Lin, Nancy U ^a   Bellon, Jennifer R ^a   Winer, Eric P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANERTINIB; CORTICOSTEROID; LAPATINIB;

BRAIN METASTASIS; BREAST CANCER; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE ASSOCIATION; HUMAN; NERVOUS SYSTEM INJURY; NEUROSURGERY; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; RADIOSURGERY; REVIEW; RISK FACTOR; BRAIN TUMOR; BREAST TUMOR; CENTRAL NERVOUS SYSTEM TUMOR; FEMALE; MENINGIOMA; METASTASIS; PATHOLOGY; SURVIVAL RATE;

BRAIN NEOPLASMS; BREAST NEOPLASMS; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; MENINGEAL NEOPLASMS; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 4444309646     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.01.175     Document Type: Review

References (100)

1. Lee Y-T: Breast carcinoma: Pattern of metastasis at autopsy. J Surg Oncol 23:175-180, 1983
2. Kesari S, Batchelor TT: Leptomeningeal metastases. Neurol Clin 21:25-66, 2003
3. Zimm S, Wampler GL, Stablein D, et al: Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 48:384-394, 1981
4. Nussbaum ES, Djalilian HR, Cho KH, et al: Brain metastases: Histology, multiplicity, surgery, and survival. Cancer 78:1781-1788, 1996
5. DiStefano A, Yap HY, Hortobagyi GN, et al: The natural history of breast cancer patients with brain metastases. Cancer 44:1913-1918, 1979
6. Engel J, Eckel R, Aydemir U, et al: Determinants and prognoses of locoregional and distant progression in breast cancer. Int J Radiat Oncol Biol Phys 55:1186-1195, 2003
7. Tsukada Y, Fouad A, Pickren JW, et al: Central nervous system metastasis from breast carcinoma. Cancer 52:2349-2354, 1983
8. Patanaphan V, Salazar OM, Risco R: Breast cancer: Metastatic patterns and their prognosis. South Med J 81:1109-1112, 1988
9. Hagemeister FB, Buzdar AU, Luna MA, et al: Causes of death in breast cancer. Cancer 46:162-167, 1980
10. Cho SY, Choi HY: Causes of death and metastatic patterns in patients with mammary cancer. Am J Clin Pathol 73:232-234, 1980
11. Hwang TL, Close TP, Grego JM, et al: Predilection of brain metastasis in gray and white matter junction and vascular border zones. Cancer 77:1551-1555, 1996
12. Maki DD, Grossman RI: Patterns of disease spread in metastatic breast carcinoma: Influence of estrogen and progesterone receptor status. Am J Neuroradiol 21:1064-1066, 2000
13. Boogerd W, Vos VW, Hart AAM, et al: Brain metastases in breast cancer; natural history, prognostic factors, and outcome. J Neurooncol 15:165-174, 1993
14. Carey LA, Ewend MG, Sawyer L, et al: Disproportionate CNS relapse after aggressive neoadjuvant chemotherapy. Breast Cancer Res Treat 69:299, 2001 (abstr 511)
15. Higashi H, Fukutomi T, Watanabe T, et al: Seven cases of breast cancer recurrence limited to the central nervous system without other visceral metastases. Breast Cancer 7:153-156, 2000
16. Samaan NA, Buzdar AU, Aldinger KA, et al: Estrogen receptor: A prognostic factor in breast cancer. Cancer 47:554-560, 1981
17. De la Monte SM, Hutchins GM, Moore GW: Estrogen and progesterone receptors in prediction of metastatic behavior of breast carcinoma. Am J Med 76:11-17, 1984
18. Siamon DJ, Clark GM, Wong WG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
19. Siamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. 244:707-712, 1989
20. Seshadri R, Firgaira FA, Horsfall DJ, et al: Clinical significance of HER-2/neu oncogens amplification in primary breast cancer. J Clin Oncol 11:1936-1942, 1993
21. Kallioniemi O-P, Holli K, Visakorpi T, et al: Association of c-erb-B-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 49:650-655, 1991
22. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
23. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
24. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
25. Burstein HJ, Kuter I, Campos SM, et al: Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 19:2722-2730, 2001
26. Pestalozzi BC, Brignoli S: Trastuzumab in CSF. J Clin Oncol 18:2350-2351, 2000
27. Burstein HJ, Lieberman G, Slamon DJ, et al: Isolated central nervous system metastases in patients with HER2 overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Breast Cancer Res Treat 82:S50-S51, 2003 (abstr 228)
28. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977, 2003
29. Weitzen R, Zach L, Kaufman B, et al: High incidence of brain metastasis in patients on trastuzumab for advanced breast cancer. Proc Am Soc Clin Oncol 21:316, 2002 (abstr 1936)
30. Wardley AM, Danson S, Clayton AJ, et al: High incidence of brain metastases in patients treated with trastuzumab for metastatic breast cancer at a large cancer center. Proc Am Soc Clin Oncol 21:61a, 2002 (abstr 241)
31. Heinrich B, Brudler O, Siekiera W, et al: Development of brain metastasis in metastatic breast cancer responding to treatment with trastuzumab. Proc Am Soc Clin Oncol 22:37, 2003 (abstr 147)
32. Crivellari D, Pagani O, Veronesi A, et al: High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Ann Oncol 12:353-356, 2001
33. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
34. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumors. Nature 406:747-752, 2000
35. van't Veer LJ, Dai H, van de Vijver MJ, et al: Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536, 2002
36. Ahr A, Karn T, Solbach C, et al: Identification of high risk breast-cancer patients by gene expression profiling. Lancet 359:131-132, 2002
37. Sorlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869-10874, 2001
38. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418-8423, 2003
39. Ramaswamy S, Ross KN, Lander ES, et al: A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49-54, 2003
40. Forsyth PA, Posner JB: Headaches in patients with brain tumors: A study of 111 patients. Neurology 43:1678-1683, 1993
41. Lassman AB, DeAngelis LM: Brain metastases. Neurol Clin 21:1-23, 2003
42. Fizazi K, Asselain B, Vincent-Salomon A, et al: Meningeal carcinomatosis in patients with breast carcinoma: Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer 77:1315-1323, 1996
43. Jeyapalan SA, Batchelor TT: Diagnostic evaluation of neurologic metastases. Cancer Invest 18:381-394, 2000
44. Davis PC, Hudgins PA, Peterman SB, et al: Diagnosis of cerebral metastases: Double-dose delayed CT vs contrast-enhanced MR imaging. Am J Neuroradiol 12:293-300, 1991
45. Akeson P, Larsson EM, Kristoffersen DT, et al: Brain metastases: Comparison of gadodiamide injection-enhanced MR imaging at standard and high dose, contrast-enhanced CT and non-contrast-enhanced MR imaging. Acta Radiol 36:300-306, 1995
46. Sze G, Milano E, Johnson C, et al: Detection of brain metastasis: Comparison of contrast-enhanced MR with unenhanced MR and enhanced CT. Am J Neuroradiol 11:785-791, 1990
47. Schellinger PD, Meinck HM, Thron A: Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 44:275-281, 1999
48. Straathof CSM, deBruin HG, Dippel DWJ, et al: The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 246:810-814, 1999
49. Collie DA, Brush JP, Lammie GA, et al: Imaging features of leptomeningeal metastases. Clin Radiol 54:765-771, 1999
50. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: Experience with 90 patients. Cancer 49:759-772, 1982
51. Rohren EM, Provenzale JM, Barboriak DP, et al: Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 226:181-187, 2003
52. Komori T, Delbeke D: Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: Detection with FDG positron emission tomography. Clin Nucl Med 26:905-907, 2001
53. Patchell RA, Tibbs PA, Walsh JW: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494-500, 1990
54. Carty NJ, Foggitt A, Hamilton CR, et al: Patterns of clinical metastasis in breast cancer: An analysis of 100 patients. Eur J Surg Oncol 21:607-608, 1995
55. Lee Y-T: Breast carcinoma: Pattern of recurrence and metastasis after mastectomy. Am J Clin Oncol 7:443-449, 1984
56. Caspar L, Scott C, Rotman M, et al: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 37:745-751, 1997
57. Lagerwaard FJ, Levendag PC, Nowak PJCM: Identification of prognostic factors in patients with brain metastases: A review of 1292 patients. Int J Radiat Oncol Biol Phys 43:795-803, 1999
58. Long DM, Hartman JF, French LA: The response of human cerebral edema to glucosteroid administration. Neurology 16:521-528, 1966
59. Weinstein JD, Toy FJ, Jaffe ME, et al: The effect of dexamethasone on brain edema in patients with metastatic brain tumors. Neurology 23:121-129, 1973
60. Ruderman NB, Hall TC: Use of glucocorticoids in the palliative treatment of metastatic brain tumors. Cancer 18:298-306, 1965
61. Mahmoud-Ahmed AS, Suh JH, Lee S-Y, et al: Results of whole brain radiotherapy in patients with brain metastases from breast cancer: A retrospective study. Int J Radiat Oncol Biol Phys 54:810-817, 2002
62. Markesbery WR, Brooks WH, Gupta GD, et al: Treatment for patients with cerebral metastases. Arch Neurol 35:754-756, 1978
63. Borgelt B, Gelber R, Kramer S, et al: The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 6:1-9. 1980
64. Borgelt B, Gelber R, Larson M, et al: Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: Final results of the first two studies by the radiation therapy oncology group. Int J Radiat Oncol Biol Phys 7:1633-1638, 1981
65. Fokstuen T, Wilking N, Rutqvist LE, et al: Radiation therapy in the management of brain metastases from breast cancer. Breast Cancer Res Treat 62:211-216, 2000
66. Cairncross JG, Kim J-H, Posner JB: Radiation therapy for brain metastases. Ann Neurol 7:529-541, 1980
67. Hendrickson FR, Lee MS, Larson M, et al: The influence of surgery and radiation therapy on patients with brain metastases. Int J Radiat Oncol Biol Phys 9:623-627, 1983
68. Noordijk EM, Vecht CJ, Haaxma-Reiche H, et al: The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 29:711-717, 1994
69. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al: Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery? Ann Neurol 33:583-590, 1993
70. Mintz AH, Kestle J, Rathbone MP, et al: A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 78:1470-1476, 1996
71. Iwadate Y, Namba H, Yamaura A: Significance of surgical resection for the treatment of multiple brain metastases. Anticancer Res 20:573-577, 2000
72. Bindal RK, Sawaya R, Leavens ME, et al: Surgical treatment of multiple brain metastases. J Neurosurg 79:210-216, 1993
73. Hazuka MB, Burleson WD, Stroud DN, et al: Multiple brain metastases are associated with poor survival in patients treated with surgery and radiotherapy. J Clin Oncol 11:369-373, 1993
74. Shaw E, Scott C, Souhami L, et al: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: Final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291-298, 2000
75. Loeffler JS, Kooy HM, Wen PY, et al: The treatment of recurrent brain metastases with stereotactic radiosurgery. J Clin Oncol 8:576-582, 1990
76. Lederman G, Wronski M, Fine M: Fractionated radiosurgery for brain metastases in 43 patients with breast carcinoma. Breast Cancer Res Treat 65:145-154, 2001
77. Firlik KS, Kondziolka D, Flickinger JC, et al: Stereotactic radiosurgery for brain metastases from breast cancer. Ann Surg Oncol 7:333-338, 2000
78. Bindal AK, Bindal RK, Hess KR, et al: Surgery versus radiosurgery in the treatment of brain metastasis. J Neurosurg 84:748-754, 1996
79. O'Neill BP, Iturria NJ, Link MJ, et al: A comparison of surgical resection and stereotactic radiosurgery in the treatment of solitary brain metastases. Int J Radiat Oncol Biol Phys 55:1169-1176, 2003
80. Auchter RM, Lamond JP, Alexander E, et al: A multi-institutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. Int J Radiat Oncol Biol Phys 35:27-35, 1996
81. Varlotto JM, Flickinger JC, Niranjan A, et al: Analysis of tumor control and toxicity in patients who have survived at least one year after radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys 57:452-464, 2003
82. Nieder C, Nestle U, Motaref B, et al: Prognostic factors in brain metastases: Should patients be selected for aggressive treatment according to recursive partitioning analysis (RPA) classes? Int J Radiat Oncol Biol Phys 46:297-302, 2000
83. Pollock BE, Brown PD, Foote RL, et al: Properly selected patients with multiple brain metastases may benefit from aggressive treatment of their intracranial disease. J Neuroonc 61:73-80, 2003
84. Swift PS, Phillips T, Martz K, et al: CT characteristics of patients with brain metastases treated in RTOG study 79-16. Int J Radiat Oncol Biol Phys 25:209-214, 1993
85. Sperduto PW, Scott C, Andrews D, et al: Stereotactic radiosurgery with whole brain radiotherapy improves survival in patients with brain metastases: Report of Radiation Therapy Oncology Group phase III study 95-08. Int J Radiat Oncol Biol Phys 54:3, 2002 (abstr)
86. Kondziolka D, Patel A, Lunsford LD, et al: Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 45:427-434, 1999
87. Van ES, Sneed PK, McDermott MW, et al: Number of brain metastases is not an important prognostic factor for survival following radiosurgery for newly-diagnosed nonmelanoma brain metastases. Int J Radiat Oncol Biol Phys 57:5131-5132. 2003 (abstr 14; suppl)
88. DeAngelis LM, Delattre JY, Posner JB: Radiation-induced dementia in patients cured of brain metastases. Neurology 39:789-796, 1989
89. Asai A, Matsutani M, Kohno T, et al: Subacute brain atrophy after radiation therapy for malignant brain tumor. Cancer 63:1962-1974, 1989
90. Sneed PK, Suh JH, Goetsch SJ, et al: A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int J Radiat Oncol Biol Phys 53:519-526, 2002
91. Hasegawa T, Kondziolka D, Flickinger JC, et al: Brain metastases treated with radiosurgery alone: An alternative to whole brain radiotherapy? Neurosurgery 52:1318-1326, 2003
92. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain. JAMA 280:1485-1489, 1998
93. Fuller BG, Kaplan ID, Adler J, et al: Stereotaxic radiosurgery for brain metastases: The importance of adjuvant whole brain irradiation. Int J Radiat Oncol Biol Phys 23:413-418, 1992
94. Pirzkall A, Debus J, Lohr F, et al: Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 16:3563-3569, 1998
95. Flickinger JC, Kondziolka D, Lunsford LD, et al: A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis. Int J Radiat Oncol Biol Phys 28:797-802, 1994
96. Robinson C, Stephans K, Fu P, et al: Impact of initial whole brain radiotherapy (WBRT) in addition to gamma knife radiosurgery (GKSRS) on the neurologic status of patients with newly diagnosed brain metastases. Int J Radiat Oncol Biol Phys 57:S326, 2003 (abstr 1109; suppl)
97. Varlotto JM, Flickinger JC, Niranjan A, et al: The impact of whole brain radiation therapy on the long-term control and morbidity of patients treated with gamma knife radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 57: S327, 2003 (suppl)
98. Regine WF, Hunn JL, Patchell RA, et al: Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: Results and implications. Int J Radiat Oncol Biol Phys 52:333-338, 2002
99. Batchelor TT, Gatineau MP, Supko JG: Pharmacologic considerations in chemotherapy for brain tumors, in Chabner BA, Longo DL (eds): Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, PA, Lippincott Williams & Wilkins, 2001. pp 657-677
100. Cordon-Cardo C, O'Brien JP, Casals D, et al: Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86:695-698, 1989